Modelling the strategies for age specific vaccination scheduling during influenza pandemic outbreaks

Mathematical Biosciences and Engineering

Volumn 8, Issue 1, 2011, Pages 123-139

  Knipl, Diána H ^a   Röst, Gergely ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

A(H1N1)v; Compartmental model; Pandemic influenza; Vaccination strategies

Indexed keywords

INFLUENZA VACCINE;

AGE; ARTICLE; BIOLOGICAL MODEL; COMPARATIVE STUDY; COMPUTER SIMULATION; HUMAN; IMMUNOLOGY; INFLUENZA; INFLUENZA VIRUS A H1N1; PANDEMIC; VIROLOGY;

AGE FACTORS; COMPUTER SIMULATION; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MODELS, IMMUNOLOGICAL; PANDEMICS;

EID: 78651354788     PISSN: 15471063     EISSN: 15510018     Source Type: Journal    
DOI: 10.3934/mbe.2011.8.123     Document Type: Article

References (46)

1. M. E. Alexander, C. S. Bowman, Z. Feng, M. Gardam, S. M. Moghadas, G. Röst, J.Wu and P. Yan, Emergence of drug-resistance: Implications for antiviral control of pandemic influenza, P. Roy. Soc. B - Biol. Sci., 274 (2007), 1675-1684.
2. M. E. Alexander, S. M. Moghadas, G. Röst and J.Wu, A delay differential model for pandemic influenza with antiviral treatment, Bulletin of Mathematical Biology, 70 (2008), 382-397.
3. J. Arino, F. Brauer, P. van den Driessche, J. Watmough and J. Wu, Simple models for containment of a pandemic, J. R. Soc. Interface, 3 (2006), 453-457.
4. P. Baccam, C. Beauchemin, C. A. Macken, F. G. Hayden and A. S. Perelson, Kinetics of influenza A virus infection in humans, J. Virol., 80 (2006), 7590-7599.
5. D. Balcan et al., Seasonal transmission potential and activity peaks of the new influenza A(H1N1): A Monte Carlo likelihood analysis based on human mobility, BMC Medicie, 7 (2009).
6. N. E. Basta, E. M. Halloran, L. Matrajt and I. M. Longini Jr., Estimating influenza vaccine efficacy from challenge and community-based study data, Am. J. Epidemiol., 168 (2008), 1343-1352.
7. G. Chowell, C. E. Ammon, N. W. Hengartner and J. M. Hyman, Transmission dynamics of the great influenza pandemic of 1918 in Geneva, Switzerland: Assessing the effects of hypothetical interventions, J. Theor. Biol., 241 (2006), 193-204.
8. G. Chowell, M. A. Miller and C. Viboud, Seasonal influenza in the United States, France and Australia: Transmission and prospects for control, Epidemiol. Infect., 136 (2007), 852-864.
9. G. Chowell, C. Viboud, X. Wang, S. Bertozzi and M. Miller, Adaptive vaccination strategies to mitigate pandemic influenza - Mexico as a case study, PLoS ONE, 4 (2009), e8164.
10. CDC, Prevention and control of influenza: Recommendations of the advisory committee on immunization practices (ACIP), July 17, 2008 / 57 (Early Release), (2008), 1-60
11. CDC, "Key Facts About Seasonal Flu Vaccine," http://www.cdc.gov/Flu/protect/keyfacts.htm, 2009.
12. O. Diekmann, J. A. P. Heesterbeek and M. G. Roberts, The construction of next-generation matrices for compartmental epidemic models, J. R. Soc. Interface, 7 (2010), 873-885
13. L. J. Donaldson, P. D. Rutter, B. M. Ellis, F. E. C. Greaves, O. T. Mytton, R. G. Pebody and I. E. Yardley, Mortality from pandemic A/H1N1 2009 influenza in England: Public health surveillance study, British Medical Journal, 339 (2009), b5213.
14. European CDC Risk Assessment, "Pandemic H1N1," Version 6, 6 November 2009.
15. Eurostat, "Population Statistics 2006 Edition," Official Publications of the European Communities (Luxembourg), 2006.
16. F. Falus and B. Oroszi, "National Chief Medical Officer's Office," Hungary, personal communication, 2009.
17. N. M. Ferguson, D. A. Cummings, C. Fraser, J. C. Cajka and P. C. Cooley, Strategies for mitigating an influence pandemic, Nature, 442 (2006), 448-452.
18. D. M. Fleming and A. J. Elliot, Estimating the risk population in relation to influenza vaccination policy, Vaccine, 24 (2006), 4378-4385.
19. M. Z. Gojovic, B. Sander, D. Fisman, M. D. Krahn and C. T. Bauch, Modelling mitigation strategies for pandemic (H1N1) 2009, Can. Med. Assoc. J., 181 (2009), 673 10.1503/cmaj.091641.
20. E. Goldstein, A. Apolloni, B. Lewis, J. C. Miller, M. Macauley, S. Eubank, M. Lipsitch and J. Wallinga, Distribution of vaccine/antivirals and the least spread line in a stratified population, J. R. Soc. Interface, 7 (2009), 755-764.
21. M. E. Greenberg, M. H. Lai, G. F. Hartel, C. H. Wichems, C. Gittleson, J. Bennet, G. Dawson, W. Hu, C. Leggio, D. Washington and R. L. Basser, Response to a monovalent influence a (H1N1) 2009 vaccine, N. Eng. J. Med., 361 (2009), 2405-2413.
22. K. Hancock, V. Veguilla, X. Lu, et al., Cross-reactive antibody responses to the 2009 pandemic H1N1 influence virus, N. Engl. J. Med., 361 (2009), 1945-1952.
23. J. M. Heffernan, R. J. Smith and L. M. Wahl, Perspectives on the basic reproductive ratio, J. R. Soc. Interface, 2 (2005), 281-293.
24. K. Johansen, A. Nicoll, B. C. Ciancio and P. Kramarz, Pandemic influence A(A(H1N1)v) 2009 vaccines in the European Union, Euro Surveill, 14 (2009), pii=19361.
25. I. M. Longini Jr and M. E. Halloran, Strategy for distribution of influence vaccine to high-risk groups and children, Am. J. Epidemiol., 161 (2005), 303.
26. L. Matrajt and I. M. Longini, "Optimizing Vaccine Allocation at Different Points in Time During an Epidemic," UW Biostatistics Working Paper Series 363, 2010.
27. J. Medlock and A. P. Galvani, Optimizing influence vaccine distribution, Science, 325 (2009), 1705-1708.
28. J. Medlock, L. A. Meyers and A. P. Galvani, "Optimizing Allocation for a Delayed Influence Vaccine Campaign," PLOS Curr Influence, RRN1134, 2010.
29. S. Merler, M. Ajelli and C. Rizzo, Age-prioritized use of antivirals during an influence pandemic, BMC Infectious Diseases, 9 (2009), 117.
30. E. Miller, K. Hoschler, P. Hardelid, E. Stanford, N. Andrews and M. Zambon, Incidence of 2009 pandemic influence A H1N1 infection in England: a cross-sectional serological study, The Lancet, 375 (2010), 1100-1108.
31. S. M. Moghadas, C. S. Bowman, G. Röst and J. Wu, Population-wide emergence of antiviral resistance during pandemic influence, PLOS ONE, 3 (2008), e1839.
32. S. M. Moghadas, C. S. Bowman, G. Röst, D. Fisman and J. Wu, Post-exposure prophylaxis during pandemic outbreaks, BMC Medicine, 3 (2009).
33. S. Moghadas, T. Day, C. Bauch, S. M. Driedger, F. Brauer, A. L. Greer, P. Yan, J. Wu, N. Pizzi and D. N. Fisman, Modelling an influence pandemic: A guide for the perplexed, Can. Med. Assoc. J., August 4, 2009, 181 (2009), 171-173.
34. J. Mossong, N. Hens, M. Nit et al., Social contacts and mixing patterns relevant to the spread of infectious diseases, PLOS Medicine, 5 (2008), e74.
35. S. D. Mylius, T. J. Hagenaars, A. K. Lugnér and J. Wallinga, Optimal allocation of pandemic influence vaccine depends on age, risk and timing, Vaccine, 26 (2008), 3742-3749.
36. K. L. Nichol, Efficacy/clinical effectiveness of inactivated influence virus vaccines in adults 1998, In: Nicholson KG, Webster RG, Hay AJ, editors. Textbook of influence. Malden, MA: Blackwell Science Ltd., (1998), 358-372.
37. H. Nishiura and K. Iwata, A simple mathematical approach to deciding the dosage of vaccine against pandemic H1N1 influence, Euro. Surveill, 14 (2009), pii=19396.
38. A. M. Presanis, D. De Angelis, A. Hagy, C. Reed, S. Riley, et al., The severity of pandemic H1N1 influence in the United States, from April to July 2009: A Bayesian analysis, PLoS Med., 6 (2009), e1000207.
39. R. Robinson, "A(H1N1)v Vaccine Products and Production, ACIP July 2009 Meeting," www.cdc.gov/vaccines/recs/acip/downloads/mtg-slides-jul09-u/ 05-Flu-Robinson.pdf.
40. R. E. Sering, I. L. Sherman and W. J. Houseworth, Excess pneumonia-influence mortality by age and sex in three major influence A2 epidemics, United States, 1957-58, 1960 and 1963, Am. J. Epidemiol., 86 (1967), 433-441.
41. V. Sypsa, I. Pavlopoulou and A. Hatzakis, "Use of an Inactivated Vaccine in Mitigating Pandemic Influence A(H1N1) Spread: A Modelling Study to Assess the Impact of Vaccination Timing and Prioritisation Strategies," Euro Surveill, 2009, pii=19356.
42. A. R. Tuite, D. N. Fisman, J. C. Kwong and A. L. Greer, Optimal pandemic influence vaccine allocation strategies for the Canadian population, PLOS ONE, 5 (2010), e10520.
43. A. R. Tuite, A. L. Greer, M. Whelan, A. L. Winter, B. Lee, P. Yan, J. Wu, S. M. Moghadas, D. Buckeridge, B. Pourbohloul and D. N. Fisman, Estimated epidemiologic parameters and morbidity associated with pandemic H1N1 influence, Can. Med. Assoc. J., 182 (2009), 131.
44. L. Vaillant, G. La Ruche, P. Barboza, for the epidemic intelligence team at InVS, Epidemiology of fatal cases associated with pandemic H1N1 influence 2009, Euro., Surveill, 14 (2009), pii=19309.
45. Z. Vajo, J. Wood, L. Kosa, I. Szilvasy, Gy. Paragh, Zs. Pauliny, K. Bartha, I. Visontay, A. Kis and I. Jankovics, A single-dose influence A (H5N1) vaccine safe and immunogenic in adult and elderly patients - an approach to pandemic vaccine development, J. Virol., 84 (2009), 1237-1242.
46. Y. Yang, J. D. Sugimoto, M. E. Halloran, N. E. Basta, D. L. Chao, L. Matrajt, G. Potter, E. Kenah and I. M. Longini Jr., The transmissibility and control of pandemic influence A (H1N1) virus, Science, 326 (2009), 729-733.